PMID- 28866662
OWN - NLM
STAT- MEDLINE
DCOM- 20180301
LR  - 20180301
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 93
IP  - 5
DP  - 2017
TI  - Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in 
      Refractory Metastatic Colorectal Cancer.
PG  - 329-335
LID - 10.1159/000479280 [doi]
AB  - PURPOSE: Regorafenib improves survival in chemorefractory metastatic colorectal 
      cancer (mCRC) patients. However, regorafenib induces various adverse events (AEs) 
      that often impair patients' quality of life. Identification of early predictive 
      markers of the efficacy is warranted. METHODS: We retrospectively examined 146 
      consecutive mCRC patients who received regorafenib. Clinical parameters, 
      including patient background, AEs, and changes in biochemical parameters until 
      day 28, were evaluated to identify efficacy predictors. RESULTS: Median 
      progression-free survival (PFS) was 2.1 months, and median overall survival was 
      6.6 months. Major AEs in all cycles were hand-foot skin reaction, hypertension, 
      and increased aspartate transaminase. We extracted 121 patients for prognostic 
      analysis. In univariate analysis, decreased carcinoembryonic antigen (HR: 0.570, 
      p = 0.012) and decreased carbohydrate antigen 19-9 (CA19-9) (HR: 0.422, p = 
      0.0012) were identified as prognostic markers of PFS. Patients in whom serum 
      CA19-9 decreased after regorafenib exhibited significantly better PFS (median 3.7 
      vs. 2.0 months, p = 0.004) than those in whom serum CA19-9 did not decrease. 
      Multivariate analysis revealed early CA19-9 decrease as an independent predictive 
      factor (HR: 0.415, 95% CI: 0.210-0.818, p = 0.011). CONCLUSION: Early response of 
      CA19-9 may predict the efficacy of regorafenib. Additional studies are needed for 
      external validation.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Komori, Azusa
AU  - Komori A
AD  - Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
FAU - Taniguchi, Hiroya
AU  - Taniguchi H
FAU - Hamauchi, Satoshi
AU  - Hamauchi S
FAU - Masuishi, Toshiki
AU  - Masuishi T
FAU - Kito, Yosuke
AU  - Kito Y
FAU - Narita, Yukiya
AU  - Narita Y
FAU - Tsushima, Takahiro
AU  - Tsushima T
FAU - Ishihara, Makoto
AU  - Ishihara M
FAU - Todaka, Akiko
AU  - Todaka A
FAU - Tanaka, Tsutomu
AU  - Tanaka T
FAU - Yokota, Tomoya
AU  - Yokota T
FAU - Kadowaki, Shigenori
AU  - Kadowaki S
FAU - Machida, Nozomu
AU  - Machida N
FAU - Ura, Takashi
AU  - Ura T
FAU - Fukutomi, Akira
AU  - Fukutomi A
FAU - Ando, Masashi
AU  - Ando M
FAU - Onozawa, Yusuke
AU  - Onozawa Y
FAU - Tajika, Masahiro
AU  - Tajika M
FAU - Yasui, Hirofumi
AU  - Yasui H
FAU - Muro, Kei
AU  - Muro K
FAU - Mori, Keita
AU  - Mori K
FAU - Yamazaki, Kentaro
AU  - Yamazaki K
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20170902
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA-19-9 Antigen)
RN  - 0 (Carcinoembryonic Antigen)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - CA-19-9 Antigen/*blood
MH  - Carcinoembryonic Antigen/blood
MH  - Colorectal Neoplasms/*blood/*drug therapy/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Prognosis
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Retrospective Studies
OTO - NOTNLM
OT  - CA19-9
OT  - Colorectal cancer
OT  - Predictive marker
OT  - Regorafenib
EDAT- 2017/09/04 06:00
MHDA- 2018/03/02 06:00
CRDT- 2017/09/04 06:00
PHST- 2017/05/05 00:00 [received]
PHST- 2017/07/06 00:00 [accepted]
PHST- 2017/09/04 06:00 [pubmed]
PHST- 2018/03/02 06:00 [medline]
PHST- 2017/09/04 06:00 [entrez]
AID - 000479280 [pii]
AID - 10.1159/000479280 [doi]
PST - ppublish
SO  - Oncology. 2017;93(5):329-335. doi: 10.1159/000479280. Epub 2017 Sep 2.